Cancer: The Research And Development Of Cancer

1978 Words4 Pages

Cancer is defined by clinicians, as unregulated cell growth leading to the invasion of surrounding tissues and spreading to other parts of the body. The human cell is created to replicate itself through the cell cycle. It consists of four phases, G1, S, G2, and M, which are controlled by proteins. Because there are various checkpoints in the cell cycle, usually division occurs without complications and reproduces normal cells. However, during these phases, when DNA replication occurs, mutations can happen. A mutation altering any gene that controls cell regulatory protein production can result in an uncontrollable growth of the cell known as cancer.
According to the American Cancer Society it is reported that there are over 1.6 million new cancer cases in the United States, every year. It is estimated that 7.6 million people die from cancer worldwide every year, out of which, 4 million people die prematurely (aged 30 to 69 years old). Being the second most common cause of death in the US, approximately 570,000 Americans died from some form of cancer in 2012, which is more than 1,500 people per day. Due to the wide varieties of cancer and their ability to grow and mutate quickly, research is difficult and expensive. With such large numbers of people affected by cancer, billions of dollars and insurmountable time are being invested in the research and development of cancer treatments. (“Cancer Facts & Figures 2013,” n.d.)
There is a wide range of treatments for cancer. These include surgery, chemotherapy, radiation, immunotherapy, hyperthermia, gene-based, stem cell transplant, photodynamic, laser, targeted, blood product donation and transfusion. There are pros and cons to each type.(“Cancer Facts & Figures 2013,” n.d...

... middle of paper ...

...ation process. This prevents the release of calcium into the cell membrane, which is the next step in the B-cell activation process. It is suspected that CD22 might also incite the B-cell activation process when stimulated by other proteins. There is very little known about CD22 ‘s positive signals, so it is unclear what could trigger these types of responses. The reason CD22 inhibits B-cell activation is not entirely known. One theory is that it acts as a control preventing B-cells from being triggered by the body’s own antigens. It is also believed that CD22 plays a part in interactions between B-cells and other cells. It is known that CD22 is important to the survival of B-cells. When there is a deficit of CD22 on the surface of B-cells they tend to begin the cycle of apoptosis.(Kantarjian et al., 2012; Sullivan-Chang et al., 2013; Walker & Smith, 2008)

More about Cancer: The Research And Development Of Cancer

Open Document